The historical rank and industry rank for Aurinia Pharmaceuticals's Net Margin % or its related term are showing as below:
FRA:IKAP'
s Net Margin % Range Over the Past 10 Years
Min: -27794.03 Med: -300.85 Max: 101.47
Current: 99.97
FRA:IKAP's Net Margin % is ranked better than 97.57% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:IKAP: 99.97
Aurinia Pharmaceuticals (FRA:IKAP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aurinia Pharmaceuticals Net Margin % Related Terms
Aurinia Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IKAP vs OCUL, NTLA, TYRA: Net Margin % Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (FRA:IKAP) has a Net Margin % of 44.21% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #23 out of 946 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Aurinia Pharmaceuticals' Net Margin % too high?
Aurinia Pharmaceuticals' current Net Margin % is 44.21%. Based on the distribution chart, Aurinia Pharmaceuticals ranks #23 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Net Margin % compare to OCUL and NTLA?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #23 out of 946 companies for Net Margin %. This places Aurinia Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Net Margin % is 44.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Modestly Overvalued. The stock's GF Value™ is €13.05, compared to a current price of €16.40 — trading 25.6% above its estimated fair value. The current Net Margin % is 44.21%. Aurinia Pharmaceuticals' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Net Margin % is 44.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of €16.40 is trading 25.6% above its estimated GF Value™ of €13.05.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for FRA:IKAP:
Net Margin %: 44.21%
GF Value™: €13.05 vs. price of €16.40 (25.6% above fair value)
No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
77GF Score
Get the complete analysis for FRA:IKAP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IKAP has been successfully added to your 
